<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: profitable unless", fill: "#536872"},
{source: "5: profitable unless", target: "5: regulatory approval", fill: "#536872"},
{source: "5: regulatory approval", target: "5: market acceptance", fill: "#536872"},
{source: "5: market acceptance", target: "5: product candidates", fill: "#536872"},
{source: "5: profitable unless", target: "8: incur losses", fill: "#cfb53b"},
{source: "8: incur losses", target: "8: next several years as", fill: "#cfb53b"},
{source: "8: next several years as", target: "8: development activities", fill: "#cfb53b"},
{source: "8: development activities", target: "8: incur significant clinical testing", fill: "#cfb53b"},
{source: "8: incur losses", target: "14: candidates", fill: "#933d41"},
{source: "14: candidates", target: "14: development", fill: "#933d41"},
{source: "14: candidates", target: "16: Preclinical ", fill: "#e6e6fa"},
{source: "16: Preclinical ", target: "16: clinical trials", fill: "#e6e6fa"},
{source: "16: clinical trials", target: "16: long expensive", fill: "#e6e6fa"},
{source: "16: Preclinical ", target: "17: collaborators several years", fill: "#f400a1"},
{source: "17: collaborators several years", target: "33: Should the CRO ", fill: "#ff9f00"},
{source: "33: Should the CRO ", target: "33: administer", fill: "#ff9f00"},
{source: "33: administer", target: "33: commercialization", fill: "#ff9f00"},
{source: "33: Should the CRO ", target: "57: additional capital by issuing securities", fill: "#deb887"},
{source: "57: additional capital by issuing securities", target: "57: through collaboration", fill: "#deb887"},
{source: "57: through collaboration", target: "57: licensing arrangements may", fill: "#deb887"},
{source: "57: licensing arrangements may", target: "57: existing stockholders", fill: "#deb887"},
{source: "57: existing stockholders", target: "57: relinquish rights", fill: "#deb887"},
{source: "57: relinquish rights", target: "57: technologies", fill: "#deb887"},
{source: "57: technologies", target: "57: product candidates", fill: "#deb887"},
{source: "57: additional capital by issuing securities", target: "60: additional", fill: "#00bfff"},
{source: "60: additional", target: "60: arrangements", fill: "#00bfff"},
{source: "60: arrangements", target: "60: collaborative", fill: "#00bfff"},
{source: "60: collaborative", target: "60: relinquish", fill: "#00bfff"},
{source: "60: relinquish", target: "60: technologies", fill: "#00bfff"},
{source: "60: technologies", target: "60: candidates", fill: "#00bfff"},
{source: "60: candidates", target: "60: commercialize", fill: "#00bfff"},
{source: "60: additional", target: "66: competitors may", fill: "#ff355e"},
{source: "66: competitors may", target: "66: new screening technologies", fill: "#ff355e"},
{source: "66: new screening technologies", target: "66: may utilize discovery techniques", fill: "#ff355e"},
{source: "66: may utilize discovery techniques", target: "66: partner with collaborators", fill: "#ff355e"},
{source: "66: partner with collaborators", target: "66: collaborators", fill: "#ff355e"},
{source: "66: collaborators", target: "66: successfully than", fill: "#ff355e"},
{source: "66: competitors may", target: "START_HERE", fill: "#ff355e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Household Products</td>
    </tr>
    <tr>
      <td>Personal Products</td>
    </tr>
    <tr>
      <td>Leisure Products</td>
    </tr>
    <tr>
      <td>Paper Products</td>
    </tr>
    <tr>
      <td>Household and Personal Products</td>
    </tr>
    <tr>
      <td>Building Products</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial_management_system">Clinical trial management system</a></td>
      <td>A Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials in clinical research. The system maintains and manages planning, performing and reporting functions, along with participant contact information, tracking deadlines and milestones.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>TELIK INC      Item 1A    <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider these <font color="blue">risk factors as each</font> of these risks     could  <font color="blue">adversely</font>  affect our business, operating results and financial     condition</td>
    </tr>
    <tr>
      <td>In those cases, the trading of our <font color="blue"><font color="blue">common stock</font> could decline</font> and     you may lose all or a part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We have a history of net losses, which we expect to continue for the next     <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We will never be <font color="blue">profitable unless</font> we develop, and obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> and <font color="blue">market <font color="blue">acceptance</font></font> of, our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue"><font color="blue">significant</font> research</font> and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font> required to     develop our TRAP <font color="blue">technology</font> and identify new <font color="blue">product <font color="blue">candidates</font></font>, and the     lack of any products to <font color="blue">generate revenue</font>, we have not <font color="blue">been profitable</font> and     have incurred operating <font color="blue">losses since</font> we were <font color="blue">incorporated</font> in 1988</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra313dtta3 million</td>
    </tr>
    <tr>
      <td>We     expect  to  <font color="blue">incur losses</font> for the next <font color="blue">several years</font> as we continue our     research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> and <font color="blue">incur <font color="blue">significant</font> clinical testing</font>     costs</td>
    </tr>
    <tr>
      <td>We do not anticipate that we <font color="blue">will generate <font color="blue">product revenue</font></font> for     <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Our losses, among other things, have caused and will cause     our <font color="blue">stockholders</font>’ equity and working capital to decrease</td>
    </tr>
    <tr>
      <td>To date, we have     <font color="blue">derived <font color="blue">substantially</font></font> all of our revenues, which have not <font color="blue">been <font color="blue">significant</font></font>,     from project <font color="blue"><font color="blue">initiation</font> fees</font> and <font color="blue">research <font color="blue">reimbursement</font> paid pursuant</font> to     existing <font color="blue">collaborative</font> <font color="blue">agreement</font>s with <font color="blue">third parties</font> and <font color="blue">achievement</font> of     <font color="blue"><font color="blue">milestones</font> under current <font color="blue"><font color="blue">collaboration</font>s</font></font></td>
    </tr>
    <tr>
      <td>We expect that this trend will     continue  until  we develop, and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> and market     <font color="blue">acceptance</font> of, our <font color="blue">product <font color="blue">candidates</font></font>, if at all</td>
    </tr>
    <tr>
      <td>We <font color="blue">may never generate</font>     <font color="blue"><font color="blue">product revenue</font> sufficient</font> to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">product <font color="blue">candidates</font></font> are in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If clinical     trials of TELCYTA or TELINTRA are delayed or <font color="blue">unsuccessful</font> or if we are     unable to complete the preclinical <font color="blue">development</font> of our other preclinical     <font color="blue">product <font color="blue">candidates</font></font>, our business may suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>testing and <font color="blue"><font color="blue">clinical trial</font>s</font> are long, expensive and uncertain     processes</td>
    </tr>
    <tr>
      <td>It may take us or our <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">several years</font> to complete     this testing, and failure can occur at any stage of the process</td>
    </tr>
    <tr>
      <td>Success in     <font color="blue">preclinical testing</font> and early <font color="blue"><font color="blue">clinical trial</font>s</font> does not ensure that later     <font color="blue"><font color="blue">clinical trial</font>s</font> will be successful, and interim results of <font color="blue"><font color="blue">clinical trial</font>s</font>     do not <font color="blue">necessarily</font> predict final results</td>
    </tr>
    <tr>
      <td>A number of companies in the     <font color="blue"><font color="blue">pharmaceutical</font> industry</font>, including bio<font color="blue">technology</font> companies, have suffered     <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue"><font color="blue">clinical trial</font>s</font>, even after promising     results in earlier <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>TELCYTA has to <font color="blue">date been evaluated</font> in Phase 1 and Phase 2 <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">three ongoing</font> Phase 3 registration trials of TELCYTA These Phase 3     <font color="blue"><font color="blue">clinical trial</font>s</font> test TELCYTA against a <font color="blue">control arm consisting</font> of currently     established standard <font color="blue">drug treatments</font> for these cancers</td>
    </tr>
    <tr>
      <td>Changes in standards     of care during our Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> may cause us to, or the FDA may     require us to, perform <font color="blue"><font color="blue">additional</font> clinical testing</font> of TELCYTA against a     <font color="blue"><font color="blue">different</font> control arm prior</font> to filing an NDA, for <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>Our     short-term <font color="blue">success depends</font> to a <font color="blue"><font color="blue">significant</font> extent on</font> the outcome of these     trials</td>
    </tr>
    <tr>
      <td>If the results of one or more of these trials do not <font color="blue">demonstrate</font>     sufficient efficacy to support our NDA, then our business may suffer</td>
    </tr>
    <tr>
      <td>We  completed  a  Phase 2 <font color="blue">clinical trial</font> of TELINTRA in MDS, a form of     pre-leukemia, to evaluate safety, <font color="blue">pharmacokinetics</font>, <font color="blue">pharmacodynamics</font> and     efficacy</td>
    </tr>
    <tr>
      <td>We received <font color="blue">permission</font> to proceed, under an IND <font color="blue"><font color="blue">application</font> filed</font>     with the FDA, with the <font color="blue">clinical study</font> of a <font color="blue">tablet formulation</font> of TELINTRA     Our  success  depends,  in  part,  on our ability to complete clinical     <font color="blue">development</font> of TELINTRA or other preclinical <font color="blue">product <font color="blue">candidates</font></font> and take     them through early <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">clinical trial</font> may fail to produce results satisfactory to the FDA     <font color="blue">Preclinical </font>and clinical data can be interpreted in <font color="blue">different</font> ways, which     could delay, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font>     results or adverse medical events during a <font color="blue">clinical trial</font> could cause a     <font color="blue">clinical trial</font> to be repeated or a program to be terminated</td>
    </tr>
    <tr>
      <td>We typically     rely on third-party clinical investigators to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font>     and, as a result, we <font color="blue">may face <font color="blue">additional</font> delays outside</font> our control</td>
    </tr>
    <tr>
      <td>We have     engaged  contract  research  <font color="blue">organizations</font>, or CROs, to <font color="blue">facilitate</font> the     <font color="blue">administration</font> of our Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> of TELCYTA <font color="blue">Dependence </font>on a     CRO <font color="blue">subjects us</font> to a number of risks</td>
    </tr>
    <tr>
      <td>Delays in identifying and engaging a     CRO may result in delays in the <font color="blue">initiation</font> of other clinical                                           14     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>trials</td>
    </tr>
    <tr>
      <td>We may not be able to control the amount and timing of resources the     CRO may devote to our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Should the CRO </font>fail to <font color="blue">administer</font> our     Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> properly, <font color="blue"><font color="blue">regulatory</font> approval</font>, <font color="blue">development</font> and     <font color="blue">commercialization</font> of TELCYTA will be delayed</td>
    </tr>
    <tr>
      <td>We do not know whether we will begin planned <font color="blue"><font color="blue">clinical trial</font>s</font> on time or     whether we will complete any of our on-going <font color="blue"><font color="blue">clinical trial</font>s</font> on schedule, if     at all</td>
    </tr>
    <tr>
      <td>We do not know whether any <font color="blue"><font color="blue">clinical trial</font>s</font> will result in marketable     products</td>
    </tr>
    <tr>
      <td>Typically, there is a high rate of failure for <font color="blue">product <font color="blue">candidates</font></font>     in preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We do not anticipate that any of our     <font color="blue">product <font color="blue">candidates</font></font> will reach the market for <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in clinical testing could materially impact our clinical     trials</td>
    </tr>
    <tr>
      <td>We do not know whether planned <font color="blue"><font color="blue">clinical trial</font>s</font> will begin on time,     will need to be revamped or will be completed on schedule, if at all</td>
    </tr>
    <tr>
      <td>In     addition to the reasons stated above, <font color="blue"><font color="blue">clinical trial</font>s</font> can be delayed for a     variety of reasons, including delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> to     commence a study, delays in <font color="blue">reaching <font color="blue">agreement</font> on</font> acceptable <font color="blue">clinical study</font>     <font color="blue">agreement</font>  terms  with prospective <font color="blue">clinical site</font>s, delays in obtaining     <font color="blue">institutional review board approval</font> to conduct a study at a prospective     <font color="blue">clinical site</font> and delays in <font color="blue">recruiting subjects</font> to <font color="blue">participate</font> in a study</td>
    </tr>
    <tr>
      <td>Delays can <font color="blue">also materially impact</font> our product <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>If we     experience delays in testing or approvals, our product <font color="blue">development</font> costs     <font color="blue">will increase</font></td>
    </tr>
    <tr>
      <td>For example, we may need to make <font color="blue"><font color="blue">additional</font> payments</font> to     third-party investigators and <font color="blue">organizations</font> to retain their services or we     may need to <font color="blue">pay recruitment incentives</font></td>
    </tr>
    <tr>
      <td>If the delays are <font color="blue">significant</font>, our     financial results and the <font color="blue">commercial prospects</font> for our <font color="blue">product <font color="blue">candidates</font></font>     will be harmed, and our ability to <font color="blue">become profitable</font> will be delayed</td>
    </tr>
    <tr>
      <td>We believe that our ability to <font color="blue">compete depends</font>, in part, on our ability to     use our <font color="blue">proprietary</font> TRAP <font color="blue">technology</font> to <font color="blue">discover new <font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>TRAP, our <font color="blue">proprietary</font> drug <font color="blue">discovery</font> <font color="blue">technology</font>, is a <font color="blue">relatively new drug</font>     <font color="blue"><font color="blue">discovery</font> method</font> that uses a <font color="blue">protein panel</font> of approximately 20 proteins     selected for their <font color="blue">distinct patterns</font> of <font color="blue">interacting with</font> small molecules</td>
    </tr>
    <tr>
      <td>This <font color="blue">panel may lack essential types</font> of interactions that we have not yet     identified, which may result in our <font color="blue">inability</font> to identify <font color="blue">active compounds</font>     that have the potential for us to develop <font color="blue">into <font color="blue">commercially</font> viable drugs</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">raise adequate</font> funds</font> in the future, we will not be able     to continue to fund our <font color="blue">operations</font>, research programs, <font color="blue">preclinical testing</font>     and <font color="blue"><font color="blue">clinical trial</font>s</font> to develop our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The process of carrying out the <font color="blue">development</font> of our own unpartnered product     <font color="blue">candidates</font> to <font color="blue">later stages</font> of <font color="blue">development</font> and developing other research     programs to the stage that they may be <font color="blue">partnered will</font> require <font color="blue">significant</font>     <font color="blue"><font color="blue">additional</font> <font color="blue"><font color="blue">expenditure</font>s</font></font>, including the <font color="blue">expenses associated with preclinical</font>     testing, <font color="blue"><font color="blue">clinical trial</font>s</font> and obtaining <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We believe that     our <font color="blue">existing cash</font> and <font color="blue">investment</font> securities will be sufficient to support     our current operating plan until the end of 2007</td>
    </tr>
    <tr>
      <td>Changes in our research     and <font color="blue">development</font> plans or other changes <font color="blue">affecting</font> our operating <font color="blue">expenses may</font>     <font color="blue">affect actual future consumption</font> of <font color="blue">existing cash</font> resources as well</td>
    </tr>
    <tr>
      <td>In any     event,  we  will  require substantial <font color="blue">additional</font> financing to fund our     <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>We do not know whether <font color="blue">additional</font> financing will     be available when needed or that, if available, we will obtain <font color="blue">financing on</font>     terms  favorable  to  our  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our     <font color="blue">accumulated deficit</font> was dlra313dtta3 million, and we expect <font color="blue">capital outlays</font> and     operating <font color="blue"><font color="blue">expenditure</font>s</font> to <font color="blue">increase over</font> the next <font color="blue">several years</font> as we expand     our clinical, research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>The extent of any actual     increase  in  operating or <font color="blue">capital spending will depend</font> in part on the     <font color="blue">clinical success</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">raise adequate</font>     funds on terms acceptable to us, if at all, we will not be able to continue     to fund our <font color="blue">operations</font>, research programs, <font color="blue">preclinical testing</font> and clinical     trials</td>
    </tr>
    <tr>
      <td>Raising <font color="blue">additional</font> capital by issuing securities or <font color="blue">through <font color="blue">collaboration</font></font>     and <font color="blue">licensing <font color="blue"><font color="blue">arrangement</font>s</font> may</font> cause dilution to existing <font color="blue">stockholders</font> or     require us to <font color="blue"><font color="blue">relinquish</font> rights</font> to our <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may seek to raise any necessary <font color="blue">additional</font> funds through equity or debt     financings, <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with corporate partners or other     sources</td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue">additional</font> capital by issuing                                           15     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font><font color="blue">equity securities</font>, our <font color="blue">stockholders</font> may experience dilution</td>
    </tr>
    <tr>
      <td>To the extent     that  we  raise  <font color="blue">additional</font>  capital through licensing <font color="blue"><font color="blue">arrangement</font>s</font> or     <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">collaborative</font> partners, we may be required to <font color="blue">relinquish</font>,     on terms that are not favorable to us, rights to some of our <font color="blue">technologies</font> or     <font color="blue">product <font color="blue">candidates</font></font> that we would otherwise seek to develop or <font color="blue">commercialize</font>     ourselves</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop and <font color="blue">market products</font> that are more <font color="blue"><font color="blue">effective</font> than</font>     our  <font color="blue">product <font color="blue">candidates</font></font> or any products that we may develop, or obtain     <font color="blue">marketing approval</font> before we do, our <font color="blue">commercial opportunity will</font> be reduced     or eliminated</td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are <font color="blue">intensely <font color="blue">competitive</font></font>     and subject to rapid and <font color="blue">significant</font> technological change</td>
    </tr>
    <tr>
      <td>Some of the drugs     that  we  are attempting to develop will have to <font color="blue">compete with existing</font>     therapies</td>
    </tr>
    <tr>
      <td>In  addition, a large number of companies are pursuing the     <font color="blue">development</font> of <font color="blue"><font color="blue">pharmaceutical</font>s</font> that target the <font color="blue">same diseases</font> and <font color="blue">conditions</font>     that  we  are  targeting</td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">competition</font> from <font color="blue">pharmaceutical</font></font> and     bio<font color="blue">technology</font> companies in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may     develop new screening <font color="blue">technologies</font> and <font color="blue">may utilize <font color="blue">discovery</font> techniques</font> or     <font color="blue">partner with <font color="blue"><font color="blue">collaborator</font>s</font></font> in order to develop products more rapidly or     <font color="blue"><font color="blue">successfully</font> than</font> we or our <font color="blue"><font color="blue">collaborator</font>s</font> are able to do</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>, <font color="blue">particularly</font> large <font color="blue">pharmaceutical</font> companies, have     <font color="blue">substantially</font> greater financial, technical and human resources than we do</td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font> also compete with us to <font color="blue">attract <font color="blue">qualified personnel</font></font> and     parties for <font color="blue">acquisition</font>s, joint ventures, licensing <font color="blue"><font color="blue">arrangement</font>s</font> or other     <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, academic institutions, government agencies and     other public and private <font color="blue">organizations</font> conducting research may seek patent     <font color="blue">protection with respect</font> to <font color="blue">potentially competing products</font> or <font color="blue">technologies</font>     and may establish exclusive <font color="blue">collaborative</font> or <font color="blue">licensing <font color="blue"><font color="blue">relationships</font> with</font></font>     our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may succeed in developing <font color="blue">technologies</font> and drugs that are     more <font color="blue">effective</font>, better tolerated or <font color="blue">less costly than</font> any which are being     developed by us or <font color="blue">which would</font> render our <font color="blue">technology</font> and <font color="blue">potential drugs</font>     obsolete and <font color="blue">non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font> may succeed in     obtaining FDA or other <font color="blue"><font color="blue">regulatory</font> approval</font>s for <font color="blue">product <font color="blue">candidates</font></font> more     <font color="blue">rapidly than us</font> or our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Any drugs resulting from our research     and <font color="blue">development</font> efforts, or from our <font color="blue">joint efforts with</font> our existing or     future <font color="blue">collaborative</font> partners, may not be able to <font color="blue">compete <font color="blue">successfully</font> with</font>     our <font color="blue">competitors</font>’ existing products or products under <font color="blue">development</font> or may not     obtain <font color="blue"><font color="blue">regulatory</font> approval</font> in the <font color="blue">United States </font>or elsewhere</td>
    </tr>
    <tr>
      <td>If we do not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to <font color="blue">market products</font> in the United     States and foreign countries, we or our <font color="blue"><font color="blue">collaborator</font>s</font> will not be permitted     to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Even if we are able to achieve success in our <font color="blue">preclinical testing</font>, we, or     our <font color="blue"><font color="blue">collaborator</font>s</font>, must provide the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>     with clinical data that <font color="blue">demonstrate</font> the safety and efficacy of our product     <font color="blue">candidates</font>  in humans before they can be approved for commercial sale</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> will prevent <font color="blue">commercialization</font> of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is subject to <font color="blue">stringent regulation by</font> a wide     range of <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether <font color="blue">regulatory</font> <font color="blue">clearance will</font> be     obtained  for  any <font color="blue">product candidate</font> that we are developing or hope to     develop</td>
    </tr>
    <tr>
      <td>A <font color="blue">pharmaceutical</font> product cannot be marketed in the <font color="blue">United States </font>    until it has completed rigorous <font color="blue">preclinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> and     an  extensive  <font color="blue">regulatory</font>  clearance  process  <font color="blue">implemented by</font> the FDA     Satisfaction of <font color="blue">regulatory</font> <font color="blue">requirements</font> typically takes many years and     depends on the type, <font color="blue">complexity</font> and novelty of the product and requires the     <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Of <font color="blue">particular significance</font> are the     <font color="blue">requirements</font> covering research and <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>,     quality control, labeling and promotion of drugs for human use</td>
    </tr>
    <tr>
      <td>Before commencing <font color="blue"><font color="blue">clinical trial</font>s</font> in humans, we, or our <font color="blue"><font color="blue">collaborator</font>s</font>, must     submit and receive <font color="blue">approval from</font> the <font color="blue">FDA of an IND </font><font color="blue">application</font></td>
    </tr>
    <tr>
      <td>We must     <font color="blue">comply with</font> FDA “Good Laboratory Practices” <font color="blue">regulations</font> in our preclinical     studies</td>
    </tr>
    <tr>
      <td>Clinical trials are subject to <font color="blue">oversight by institutional review</font>     boards of participating <font color="blue">clinical site</font>s and the FDA and:           •   must be conducted in conformance with the FDA <font color="blue">regulations</font>;                                           16     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>  •   must meet <font color="blue">requirements</font> for <font color="blue">institutional review board approval</font>;           •   must meet <font color="blue">requirements</font> for <font color="blue">informed consent</font>;           •   must meet <font color="blue">requirements</font> for Good Clinical Practices;           •   may require large numbers of <font color="blue">participants</font>; and           •   may be <font color="blue">suspended by us</font>, our <font color="blue"><font color="blue">collaborator</font>s</font> or the FDA at any time if it     is believed that the <font color="blue">subjects participating</font> in these trials are being     exposed to unacceptable <font color="blue">health risks</font> or if the FDA <font color="blue">finds deficiencies</font> in the     IND <font color="blue">application</font> or the conduct of these trials</td>
    </tr>
    <tr>
      <td>Before receiving FDA clearance to market a product, we, or our <font color="blue"><font color="blue">collaborator</font>s</font>     must <font color="blue">demonstrate</font> that the <font color="blue">product candidate</font> is safe and <font color="blue">effective</font> in the     <font color="blue">patient population</font> that will be treated</td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font> results or     adverse medical events during a <font color="blue">clinical trial</font> could cause a <font color="blue">clinical trial</font>     to be repeated, a program to be terminated and could delay approval</td>
    </tr>
    <tr>
      <td>We     typically rely on third-party clinical investigators to conduct our clinical     trials and other third-party <font color="blue">organizations</font> to perform <font color="blue">data collection</font> and     analysis</td>
    </tr>
    <tr>
      <td>As a result, we may face <font color="blue">additional</font> delaying factors outside our     control</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may encounter delays</font> or <font color="blue">rejections based upon</font>     <font color="blue">additional</font> government regulation from future legislation or <font color="blue">administrative</font>     action or changes in FDA policy or <font color="blue">interpretation during</font> the period of     product <font color="blue">development</font>, <font color="blue"><font color="blue">clinical trial</font>s</font> and FDA <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>Failure to     <font color="blue">comply with</font> applicable FDA or other applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> may     result  in criminal prosecution, civil penalties, recall or seizure of     products, total or <font color="blue">partial suspension</font> of production or injunction, as well     as other <font color="blue">regulatory</font> action</td>
    </tr>
    <tr>
      <td>We have limited experience in conducting and     managing the <font color="blue"><font color="blue">clinical trial</font>s</font> necessary to obtain <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font> clearance of a product is granted, this <font color="blue">clearance will</font> be     limited to those disease states and <font color="blue">conditions</font> for which the product is     <font color="blue">demonstrate</font>d through <font color="blue"><font color="blue">clinical trial</font>s</font> to be safe and <font color="blue">efficacious</font>, which could     limit our <font color="blue">market opportunity</font></td>
    </tr>
    <tr>
      <td>Furthermore, product approvals, once granted,     may be withdrawn if problems occur after <font color="blue">initial marketing</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font>     that any compound developed by us, alone or with others, will prove to be     safe and <font color="blue">efficacious</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> and will meet all of the applicable     <font color="blue">regulatory</font> <font color="blue">requirements</font> needed to receive <font color="blue">marketing clearance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory     </font>clearance may also contain <font color="blue">requirements</font> for costly post-marketing testing     and surveillance to monitor the safety and efficacy of the product</td>
    </tr>
    <tr>
      <td>If     problems occur after <font color="blue">initial marketing</font>, such as the <font color="blue">discovery</font> of <font color="blue">previously</font>     unknown  <font color="blue">problems with</font> our <font color="blue">product <font color="blue">candidates</font></font>, including <font color="blue">unanticipated</font>     <font color="blue">adverse events</font> or <font color="blue">adverse events</font> of <font color="blue">unanticipated</font> severity or frequency, or     <font color="blue"><font color="blue">manufacture</font>r</font> or <font color="blue">manufacturing</font> issues, <font color="blue">marketing approval</font> can be withdrawn</td>
    </tr>
    <tr>
      <td>Outside  the United States, the ability to market a product depends on     receiving  a  marketing  <font color="blue">authorization</font> from the <font color="blue">appropriate</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>This foreign <font color="blue"><font color="blue">regulatory</font> approval</font> process typically includes all     of the <font color="blue">risks associated with</font> FDA <font color="blue">clearance described</font> above and may include     <font color="blue">additional</font> risks</td>
    </tr>
    <tr>
      <td>As our <font color="blue">product programs advance</font>, we will need to hire <font color="blue">additional</font> scientific     and <font color="blue"><font color="blue">management</font> personnel</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> efforts will be     <font color="blue">seriously jeopardized</font> if we are unable to attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on the <font color="blue">continued contributions</font> of our principal     <font color="blue">management</font>  and <font color="blue">scientific personnel</font> and on our ability to develop and     maintain  important  <font color="blue"><font color="blue"><font color="blue">relationships</font> with</font> leading academic institutions</font>,     <font color="blue">scientists</font>  and  companies in the face of <font color="blue">intense <font color="blue">competition</font></font> for such     personnel</td>
    </tr>
    <tr>
      <td>As we plan for and commence <font color="blue">additional</font> advanced <font color="blue"><font color="blue">clinical trial</font>s</font>,     including Phase 2 and Phase 3, we will also need to <font color="blue">further expand</font> our     clinical <font color="blue">development</font> personnel</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">research programs depend on</font>     our  ability  to  attract and retain <font color="blue">highly skilled chemists</font> and other     <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>Wick or any of our other key     personnel, our research and <font color="blue">development</font> efforts could be seriously and     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">generally</font> <font color="blue">entered into</font> consulting</font> or other     <font color="blue">agreement</font>s with our scientific and clinical <font color="blue"><font color="blue">collaborator</font>s</font> and advisors</td>
    </tr>
    <tr>
      <td>Wick or any of our other     <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>There is currently a shortage of <font color="blue">skilled executives</font> and     <font color="blue">employees with technical expertise</font> in the bio<font color="blue">technology</font> industry and this     shortage is likely to continue</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">competition</font> among numerous     companies, academic and other <font color="blue">research institutions</font> for                                           17     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font><font color="blue">skilled personnel</font> and experienced <font color="blue">scientists</font> is intense and <font color="blue">turnover rates</font>     are high</td>
    </tr>
    <tr>
      <td>The cost of living in the <font color="blue">San Francisco Bay Area </font>is very high     compared to other parts of the country, which may <font color="blue">adversely</font> affect our     ability to compete for <font color="blue">qualified personnel</font> and <font color="blue">will increase</font> costs</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Because  </font>   </font>of this <font color="blue">competitive</font> <font color="blue">environment</font>, we have encountered and <font color="blue">may continue</font> to     encounter increasing <font color="blue"><font color="blue">difficult</font>y</font> in attracting <font color="blue">qualified personnel</font> as our     <font color="blue">operations</font> expand and the demand for these <font color="blue">professionals increases</font> and this     <font color="blue"><font color="blue">difficult</font>y</font> could <font color="blue">significant</font>ly impede the <font color="blue">achievement</font> of our research and     <font color="blue">development</font> objectives</td>
    </tr>
    <tr>
      <td>If physicians and patients do not <font color="blue">accept products</font> that we may develop, our     ability  to  generate  <font color="blue">product revenue</font> in the <font color="blue">future will</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td><font color="blue">Products  </font>that  we  may  develop  may not gain <font color="blue">market <font color="blue">acceptance</font></font> among     physicians, healthcare payors, patients and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td><font color="blue">Market     </font><font color="blue">acceptance</font> of and demand for any products that we may develop <font color="blue">will depend on</font>     many factors, including the following:           •   our ability to provide acceptable evidence of safety and efficacy;           •   convenience and ease of <font color="blue">administration</font>;           •   cost <font color="blue">effective</font>ness;           •   the <font color="blue">effective</font>ness of our <font color="blue">marketing strategy</font> and the pricing of any     products that we may develop;           •   our ability to obtain third-party coverage or <font color="blue">reimbursement</font>; and           •   the prevalence and severity of adverse side effects</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may elect not to <font color="blue">recommend products</font> that we may develop even if     our <font color="blue">products meet</font> the above criteria</td>
    </tr>
    <tr>
      <td>If any product that we may develop     fails to achieve <font color="blue">market <font color="blue">acceptance</font></font>, we may not be able to <font color="blue">successfully</font>     market and sell that product, <font color="blue">which would</font> limit our ability to generate     revenue and <font color="blue">adversely</font> affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">licensees cannot</font> obtain and defend our <font color="blue">respective intellectual</font>     <font color="blue">property rights</font>, or if our <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">technologies</font> or any products     that we may develop are found to <font color="blue">infringe patents</font> of <font color="blue">third parties</font>, we could     <font color="blue">become involved</font> in lengthy and <font color="blue">costly legal proceedings</font> that could <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success will depend</font> in a large part on our own and our licensees’     ability  to  obtain  and  defend  patents  for each party’s respective     <font color="blue">technologies</font> and the compounds and other products, if any, resulting from     the  <font color="blue">application</font>  of  these  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The  patent  positions  of     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies can be <font color="blue">highly uncertain</font> and     <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>As a result, the degree of     future protection for our <font color="blue">proprietary</font> rights is uncertain, and we cannot     assure you that:           •   we were the first to make the <font color="blue">inventions</font> covered by each of our     pending patent <font color="blue">application</font>s;           •   we were the first to file patent <font color="blue">application</font>s for these <font color="blue">inventions</font>;           •   others will not <font color="blue">in<font color="blue">dependent</font>ly</font> develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or duplicate any of our <font color="blue">technologies</font>;           •   any of our pending patent <font color="blue">application</font>s will result in <font color="blue">issued patents</font>;           •   any <font color="blue">patents issued</font> to us or our <font color="blue"><font color="blue">collaborator</font>s</font> will provide a basis for     <font color="blue">commercially</font> viable products, will provide us with any <font color="blue">competitive</font>     <font color="blue">advantages</font> or will not be challenged by <font color="blue">third parties</font>;           •   any of our <font color="blue">issued patents</font> will be valid or enforceable; or           •   we will develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that are     patentable</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot predict</font> the breadth of claims allowed in our or other     companies’ patents</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>For  TRAP,  we  hold patents in the <font color="blue">United States </font>and <font color="blue">internationally</font>,     including a pending foreign <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>These patents, and any patent that     <font color="blue">may issue on</font> the pending <font color="blue">application</font>, will expire between 2014 and 2015</td>
    </tr>
    <tr>
      <td>For     TELCYTA, we hold <font color="blue">compound patents</font> in the <font color="blue">United States </font>and <font color="blue">internationally</font>,     including a pending foreign <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>These patents, and any patent that     <font color="blue">may issue on</font> the pending <font color="blue">application</font>, will expire in 2013 and 2014</td>
    </tr>
    <tr>
      <td>For     TELINTRA, we hold <font color="blue">compound patents</font> in the <font color="blue">United States </font>and <font color="blue">internationally</font>,     including a pending foreign <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>These patents, and any patent that     <font color="blue">may issue on</font> the pending <font color="blue">application</font>, will expire in 2014</td>
    </tr>
    <tr>
      <td>We can <font color="blue">generally</font>     apply for <font color="blue">patent term extensions on</font> the patents for TELCYTA and TELINTRA     when and if <font color="blue">marketing approval</font>s for these compounds are obtained in the     <font color="blue">relevant countries</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font>, in part, on our ability to operate without     infringing the intellectual <font color="blue">property rights</font> of others</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that our <font color="blue"><font color="blue">activities</font> will</font> not <font color="blue">infringe patents</font> owned by others</td>
    </tr>
    <tr>
      <td>As of the     date of this annual report, we have not received any <font color="blue">communications with</font> the     owners  of related patents alleging that our <font color="blue"><font color="blue">activities</font> infringe</font> their     patents</td>
    </tr>
    <tr>
      <td>However, if our <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">technologies</font> or any products     that we may develop are found to <font color="blue">infringe patents</font> issued to <font color="blue">third parties</font>,     the <font color="blue">manufacture</font>, use and sale of any products that we may develop could be     enjoined, and we could be required to pay substantial damages</td>
    </tr>
    <tr>
      <td>In addition,     we may be required to obtain licenses to patents or other <font color="blue">proprietary</font> rights     of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any licenses required under any     such  patents  or  <font color="blue">proprietary</font> rights would be made <font color="blue">available on terms</font>     acceptable  to  us,  if  at all</td>
    </tr>
    <tr>
      <td>Failure to obtain such licenses could     <font color="blue">negatively</font> affect our business</td>
    </tr>
    <tr>
      <td>Others  may  have filed and in the future may file patent <font color="blue">application</font>s     covering small molecules or <font color="blue">therapeutic products</font> that are similar to ours</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our patent <font color="blue">application</font>s will have <font color="blue">priority over</font>     patent <font color="blue">application</font>s filed by others</td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action against us</font> or our     <font color="blue"><font color="blue">collaborator</font>s</font> claiming damages and seeking to <font color="blue">enjoin commercial <font color="blue">activities</font></font>     relating  to the affected products and processes could, in addition to     subjecting  us  to  <font color="blue">potential <font color="blue">liability</font></font> for damages, require us or our     <font color="blue"><font color="blue">collaborator</font>s</font> to obtain a license to continue to <font color="blue">manufacture</font> or market the     affected  products and processes</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether we, or our     <font color="blue"><font color="blue">collaborator</font>s</font>, would prevail in any of these actions or that any license     required under any of these <font color="blue">patents would</font> be made <font color="blue">available on <font color="blue">commercially</font></font>     acceptable  terms, if at all</td>
    </tr>
    <tr>
      <td>We believe that there may be <font color="blue">significant</font>     <font color="blue">litigation</font> in the industry regarding patent and other <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font> in <font color="blue">litigation</font>, it <font color="blue">could consume</font> a substantial     portion  of  our managerial and <font color="blue">financial resources</font>, and we may not be     successful in any such <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In  addition,  we  could  incur  substantial  costs and use of our key     employees’ time and efforts in <font color="blue">litigation</font> if we are required to defend     against patent suits brought by <font color="blue">third parties</font> or if we initiate these suits,     and we <font color="blue">cannot predict</font> whether we would be able to prevail in any of these     suits</td>
    </tr>
    <tr>
      <td>Furthermore, some of our patents and intellectual <font color="blue">property rights</font> are owned     <font color="blue">jointly by us</font> and our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>While there are legal and <font color="blue">contractual</font>     <font color="blue">restraints on</font> the rights of these <font color="blue">joint owners</font>, they may use these patents     and other <font color="blue">intellectual property</font> in ways that may harm our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on <font color="blue">trade secrets</font></font> to protect <font color="blue">technology</font>, including aspects of     our TRAP <font color="blue">technology</font>, where we believe <font color="blue">patent protection</font> is not <font color="blue">appropriate</font>     or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>While we     require employees, academic <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">consultants</font> to <font color="blue">enter into</font>     <font color="blue">confidentiality</font> <font color="blue">agreement</font>s, we may not be able to <font color="blue">adequately protect</font> our     trade  secrets  or  other  <font color="blue">proprietary</font> information in the event of any     <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> or the lawful <font color="blue">development</font> by others of such     information</td>
    </tr>
    <tr>
      <td>If the identity of specific proteins or other elements of our     TRAP <font color="blue">technology</font> become known, our <font color="blue">competitive</font> advantage in drug <font color="blue">discovery</font>     could be reduced</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">collaborator</font>s</font> and scientific advisors have <font color="blue">publication</font> and other     rights to certain information and <font color="blue">data gained from</font> their <font color="blue">collaboration</font> and     <font color="blue">research with us</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">publication</font> or other <font color="blue">use could limit</font> our ability to     secure intellectual <font color="blue">property rights</font> or impair any <font color="blue">competitive</font> advantage that     we  may  possess  or realize by maintaining the <font color="blue">confidentiality</font> of the     information or data</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>We <font color="blue">will depend on</font> <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> to complete the <font color="blue">development</font> and     <font color="blue">commercialization</font> of some of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font> may place the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> outside of     our control, may require us to <font color="blue">relinquish</font> important rights or <font color="blue">may otherwise</font>     not be on terms favorable to us</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">enter into</font> <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font> for     clinical  trials,  <font color="blue">development</font>, <font color="blue">manufacturing</font>, <font color="blue"><font color="blue">regulatory</font> approval</font>s or     <font color="blue">commercialization</font> of some of our <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">particularly</font> outside     North America, or in <font color="blue">disease areas</font> requiring larger and <font color="blue">longer clinical</font>     trials</td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> will subject us to a number     of risks</td>
    </tr>
    <tr>
      <td>We may not be able to control the amount and timing of resources     our  <font color="blue">collaborative</font>  <font color="blue">partners may devote</font> to the <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborative</font> partners may experience financial <font color="blue">difficult</font>ies</td>
    </tr>
    <tr>
      <td>Should a     <font color="blue">collaborative</font> partner fail to develop or <font color="blue">commercialize</font> a compound or product     candidate to which it has rights from us, we may not receive any future     milestone payments and will not receive any royalties for this compound or     product  candidate</td>
    </tr>
    <tr>
      <td>Business <font color="blue">combinations</font> or <font color="blue">significant</font> changes in a     <font color="blue">collaborative</font>  partner’s business strategy may also <font color="blue">adversely</font> affect a     partner’s willingness or ability to complete its <font color="blue">obligations under</font> the     <font color="blue">arrangement</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">agreement</font>s on     favorable terms, our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     could be materially <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">collaboration</font>s</font> are for early stage programs and allow partners     <font color="blue">significant</font> <font color="blue">discretion</font> in electing whether to pursue any of the planned     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We do not anticipate <font color="blue">significant</font> revenues to result from these     <font color="blue"><font color="blue">relationships</font> until</font> the <font color="blue">collaborator</font> has advanced <font color="blue">product <font color="blue">candidates</font></font> into     <font color="blue"><font color="blue">clinical trial</font>s</font>, which will not occur for <font color="blue">several years</font>, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">arrangement</font>s</font> are subject to <font color="blue">numerous risks</font>, including the right of the     <font color="blue">collaboration</font> partner to control the timing of the research and <font color="blue">development</font>     efforts, the <font color="blue">advancement</font> of lead <font color="blue">product <font color="blue">candidates</font></font> to <font color="blue"><font color="blue">clinical trial</font>s</font> and     the <font color="blue">commercialization</font> of <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, a <font color="blue">collaborative</font>     partner could <font color="blue">in<font color="blue">dependent</font>ly</font> move <font color="blue">forward with</font> a <font color="blue">competing lead candidate</font>     developed either <font color="blue">in<font color="blue">dependent</font>ly</font> or in <font color="blue">collaboration</font> with others, including     our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font> or maintain <font color="blue">existing contracts with third</font>     parties to <font color="blue">manufacture</font> our <font color="blue">product <font color="blue">candidates</font></font> or any products that we may     develop  in  <font color="blue">sufficient quantities</font> and at an acceptable cost, clinical     <font color="blue">development</font> of <font color="blue">product <font color="blue">candidates</font></font> could be delayed and we may be unable to     meet demand for any products that we may develop and <font color="blue">lose potential revenue</font></td>
    </tr>
    <tr>
      <td>We  do  not currently operate <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> for clinical or     <font color="blue">commercial production</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect to continue to     rely on <font color="blue">third parties</font> for the <font color="blue">manufacture</font> of our <font color="blue">product <font color="blue">candidates</font></font> and any     products that we may develop</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently lack</font> the resources and <font color="blue">capability</font>     to <font color="blue">manufacture</font> any of our <font color="blue">product <font color="blue">candidates</font></font> on a <font color="blue">clinical scale</font> or any     products that we may develop on a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>As a result, we will be     <font color="blue">dependent</font> on corporate partners, licensees or other <font color="blue">third parties</font> for the     <font color="blue">manufacturing</font> of clinical and <font color="blue">commercial scale</font> quantities of our product     <font color="blue">candidates</font> and any products that we may develop</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> and     any products that we may develop may be in <font color="blue">competition</font> with other product     <font color="blue">candidates</font> and products for access to these <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>For this and other     reasons, our <font color="blue"><font color="blue">collaborator</font>s</font> or <font color="blue">third parties</font> may not be able to <font color="blue">manufacture</font>     these <font color="blue">product <font color="blue">candidates</font></font> and products in a cost <font color="blue">effective</font> or <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>While we currently possess <font color="blue">sufficient inventory</font> of TELCYTA and TELINTRA that     are stored in <font color="blue">multiple locations</font> and an <font color="blue">additional</font>, substantial quantity of     the active ingredient in TELCYTA, if these <font color="blue">inventories</font> are lost or damaged,     the clinical <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> or their submission for     <font color="blue">regulatory</font>  approval  could be delayed, and our ability to deliver any     products  that  we  may develop on a <font color="blue">timely basis could</font> be impaired or     precluded</td>
    </tr>
    <tr>
      <td>We  are currently <font color="blue">dependent</font> on a <font color="blue">single source</font> of supply of the active     ingredient in TELCYTA, Organichem Corporation</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">entered into</font> an     <font color="blue">agreement</font> with, and are working to qualify, an <font color="blue">additional</font> supplier, there is     <font color="blue">no certainty</font> this will occur</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently <font color="blue">depend upon</font> two sources</font> for the     drug product <font color="blue">manufacture</font> of TELCYTA         We <font color="blue">currently <font color="blue">depend upon</font> two sources</font> of supply for <font color="blue">clinical quantities</font> of     the active ingredient in TELINTRA We <font color="blue">depend upon</font> a <font color="blue">single source</font> of supply     for <font color="blue">key excipients used</font> in the <font color="blue">manufacture</font> of TELINTRA, Lipoid GmbH While     we are evaluating potential <font color="blue">alternative</font> sources of these materials, we have     no such <font color="blue">alternative</font> sources that are <font color="blue">immediately available</font></td>
    </tr>
    <tr>
      <td>We currently     <font color="blue">depend upon</font> two sources for the drug product <font color="blue">manufacture</font> of TELINTRA                                           20     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>If <font color="blue">manufacturing</font> is not performed in a <font color="blue">timely manner</font>, if our suppliers fail     to perform or if our <font color="blue"><font color="blue">relationships</font> with</font> our suppliers or <font color="blue"><font color="blue">manufacture</font>r</font>s     <font color="blue">should terminate</font>, our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">commercialization</font> of TELCYTA and     TELINTRA could be delayed</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into</font> or maintain any     necessary third-party <font color="blue">manufacturing</font> <font color="blue"><font color="blue">arrangement</font>s</font> on acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">current <font color="blue">dependence upon others</font></font> for the <font color="blue">manufacture</font> of our product     <font color="blue">candidates</font> and our anticipated <font color="blue">dependence upon others</font> for the <font color="blue">manufacture</font> of     any products that we may develop may <font color="blue">adversely</font> affect our <font color="blue">future profit</font>     margins and our ability to <font color="blue">commercialize</font> any products that we may develop on     a timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>If we are unable to create sales, marketing and <font color="blue"><font color="blue">distribution</font> capabilities</font> or     <font color="blue">enter into</font> <font color="blue">agreement</font>s with <font color="blue">third parties</font> to perform these functions, we will     not be able to <font color="blue">commercialize</font> any products that we may develop</td>
    </tr>
    <tr>
      <td>We currently have no sales, marketing or <font color="blue"><font color="blue">distribution</font> capabilities</font></td>
    </tr>
    <tr>
      <td>In order     to  <font color="blue">commercialize</font> any products that we may develop, we <font color="blue">must internally</font>     develop  sales,  marketing  and <font color="blue"><font color="blue">distribution</font> capabilities</font> or establish     <font color="blue"><font color="blue">collaboration</font>s</font> or other <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font> to perform these     services</td>
    </tr>
    <tr>
      <td>We intend to market some products that we may develop directly in     <font color="blue">North America </font>and rely on <font color="blue"><font color="blue">relationships</font> with</font> one or more <font color="blue">pharmaceutical</font>     companies with established <font color="blue">distribution</font> systems and direct sales forces to     market other products that we may develop and address other markets</td>
    </tr>
    <tr>
      <td>We may     not be able to establish in-house sales and <font color="blue"><font color="blue">distribution</font> capabilities</font> or     <font color="blue">relationships</font>  with  third  parties</td>
    </tr>
    <tr>
      <td>To the extent that we <font color="blue">enter into</font>     co-promotion or other licensing <font color="blue"><font color="blue">arrangement</font>s</font>, any <font color="blue">product revenue</font>s are     likely to be lower than if we <font color="blue">directly marketed</font> and sold any products that     we may develop, and any revenues we receive will <font color="blue">depend upon</font> the efforts of     <font color="blue">third parties</font>, whose efforts may not be successful</td>
    </tr>
    <tr>
      <td>Budget <font color="blue">constraints may force us</font> to delay our efforts to develop certain     <font color="blue">product <font color="blue">candidates</font></font> in favor of developing others, which may prevent us from     <font color="blue">commercializing</font> all <font color="blue">product <font color="blue">candidates</font></font> as quickly as possible</td>
    </tr>
    <tr>
      <td>Because we have limited resources, and because research and <font color="blue">development</font> is     an <font color="blue">expensive process</font>, we <font color="blue">must regularly assess</font> the <font color="blue">most efficient allocation</font>     of  our  research  and <font color="blue">development</font> budget</td>
    </tr>
    <tr>
      <td>As a result, we may have to     prioritize <font color="blue">development</font> <font color="blue">candidates</font> and may not be able to fully realize the     value of some of our <font color="blue">product <font color="blue">candidates</font></font> in a <font color="blue">timely manner</font>, as they will be     delayed in reaching the market, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font> lawsuits</font> are <font color="blue">successfully</font> brought against us, we may     incur substantial <font color="blue">liabilities</font> and may be required to limit <font color="blue">commercialization</font>     of our <font color="blue">product <font color="blue">candidates</font></font> and any products that we may develop</td>
    </tr>
    <tr>
      <td>The testing and marketing of <font color="blue">medical products entail</font> an <font color="blue">inherent risk</font> of     product  <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  are  not aware of any historical or     anticipated product <font color="blue">liability</font> claims or specific causes for concern, if we     cannot <font color="blue">successfully</font> defend ourselves against product <font color="blue">liability</font> claims, we     may incur substantial <font color="blue">liabilities</font> or be required to limit <font color="blue">commercialization</font>     of our <font color="blue">product <font color="blue">candidates</font></font> and any products that we may develop</td>
    </tr>
    <tr>
      <td>In addition,     product <font color="blue">liability</font> claims may also result in withdrawal of <font color="blue">clinical trial</font>     volunteers, injury to our reputation and <font color="blue">decreased demand</font> for any products     that we may <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>We currently carry product <font color="blue">liability</font> insurance     that covers our <font color="blue"><font color="blue">clinical trial</font>s</font> up to a dlra10 million annual aggregate limit</td>
    </tr>
    <tr>
      <td>We  will need to increase the amount of coverage if and when we have a     product  that  is  <font color="blue">commercially</font>  available</td>
    </tr>
    <tr>
      <td>If we are unable to obtain     sufficient product <font color="blue">liability</font> insurance at an acceptable cost, potential     product <font color="blue">liability</font> claims <font color="blue">could prevent</font> or inhibit the <font color="blue">commercialization</font> of     any products that we may develop, alone or with corporate <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">use biological</font> and <font color="blue">hazardous materials</font> in a manner that causes injury,     we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> involve the <font color="blue">controlled use</font> of     potentially harmful biological materials, <font color="blue">hazardous materials</font>, chemicals and     various radio<font color="blue">active compounds</font>, and are subject to federal, state                                           21     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>and local laws and <font color="blue">regulations</font> governing the use, storage, handling and     disposal  of  these  materials and specified waste products</td>
    </tr>
    <tr>
      <td>We cannot     eliminate the risk of <font color="blue">accidental <font color="blue">contamination</font></font> or <font color="blue">injury from</font> the use,     storage, handling or disposal of these materials</td>
    </tr>
    <tr>
      <td>We currently have several     <font color="blue">coverages applying</font> to <font color="blue">various types</font> of biological and <font color="blue">pollution exposures</font>     for  a  total  amount  of dlra350cmam000 in insurance, which we believe is a     <font color="blue">reasonably adequate amount</font> to <font color="blue">insulate us from damage</font> claims arising from     our use of <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>However, in the event of <font color="blue">contamination</font> or     injury, we could be held liable for damages that result, and any <font color="blue">liability</font>     could <font color="blue">significant</font>ly exceed our coverage and resources</td>
    </tr>
    <tr>
      <td>We have implemented anti-takeover provisions which could discourage or     prevent  a takeover, even if an <font color="blue"><font color="blue">acquisition</font> would</font> be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font> and <font color="blue">may prevent <font color="blue">attempts by</font></font> our <font color="blue">stockholders</font> to replace or     remove our current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and     bylaws, as well as provisions <font color="blue">of Delaware </font>law, could make it more <font color="blue">difficult</font>     for a third-party to acquire us, even if doing so would be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">provisions may frustrate</font> or prevent any     <font color="blue">attempts by</font> our <font color="blue">stockholders</font> to replace or remove our current <font color="blue">management</font> by     making it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to <font color="blue">replace members</font> of our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Because our board of <font color="blue">directors</font> is responsible for appointing the     members of our <font color="blue">management</font> team, these <font color="blue">provisions could</font> in turn affect any     <font color="blue">attempt by</font> our <font color="blue">stockholders</font> to <font color="blue">replace current members</font> of our <font color="blue">management</font>     team</td>
    </tr>
    <tr>
      <td>These provisions include:           •   <font color="blue">establishing</font> a <font color="blue">classified board</font> of <font color="blue">directors</font> requiring that members of     the board be elected in <font color="blue">different</font> years, which lengthens the time needed to     elect a <font color="blue">new majority</font> of the board;           •   <font color="blue">authorizing</font> the issuance of “blank check” preferred stock that could     be issued by our board of <font color="blue">directors</font> to increase the number of outstanding     shares or change the balance of <font color="blue">voting control</font> and thwart a takeover     attempt;           •   <font color="blue">prohibiting cumulative voting</font> in the election of <font color="blue">directors</font>, which     <font color="blue">would otherwise allow</font> for less than a majority of <font color="blue">stockholders</font> to elect     director <font color="blue">candidates</font>;           •   limiting the ability of <font color="blue">stockholders</font> to <font color="blue">call special meetings</font> of the     <font color="blue">stockholders</font>;           •   <font color="blue">prohibiting stockholder action by written consent</font> and requiring all     <font color="blue">stockholder actions</font> to be taken at a meeting of our <font color="blue">stockholders</font>; and           •   <font color="blue">establishing</font> 90 to 120 day advance notice <font color="blue">requirements</font> for <font color="blue">nominations</font>     for election to the board of <font color="blue">directors</font> and for <font color="blue">proposing matters</font> that can be     acted upon by <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>We adopted a <font color="blue">stockholder rights</font> plan that may discourage, delay or prevent a     merger or <font color="blue">acquisition</font> that is <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2001, our board of <font color="blue">directors</font> adopted a <font color="blue">stockholder rights</font> plan     that may have the effect of discouraging, delaying or preventing a merger or     <font color="blue">acquisition</font> that is <font color="blue">beneficial</font> to our <font color="blue">stockholders</font> by diluting the ability     of a <font color="blue">potential acquiror</font> to acquire us</td>
    </tr>
    <tr>
      <td>Pursuant to the terms of our plan,     when a person or group, <font color="blue">except under certain circumstances</font>, acquires 20prca or     more of our <font color="blue">outstanding <font color="blue">common stock</font></font> or 10 business days after <font color="blue">commencement</font>     or  <font color="blue">announcement</font>  of a tender or <font color="blue">exchange offer</font> for 20prca or more of our     <font color="blue">outstanding <font color="blue">common stock</font></font>, the rights (except those rights held by the person     or group who has acquired or announced an offer to acquire 20prca or more of     our <font color="blue">outstanding <font color="blue">common stock</font></font>) would <font color="blue">generally</font> become exercisable for shares     of our <font color="blue"><font color="blue">common stock</font> at</font> a discount</td>
    </tr>
    <tr>
      <td>Because the <font color="blue">potential acquiror</font>’s rights     would not become exercisable for our shares of <font color="blue"><font color="blue">common stock</font> at</font> a discount,     the <font color="blue">potential acquiror</font> would suffer substantial dilution and may lose its     ability to acquire us</td>
    </tr>
    <tr>
      <td>In addition, the existence of the plan <font color="blue">itself may</font>     deter  a  <font color="blue">potential acquiror</font> from acquiring us</td>
    </tr>
    <tr>
      <td>As a result, either by     operation of the plan or by its <font color="blue">potential deterrent</font> effect, mergers and     <font color="blue">acquisition</font>s  of  us  that our <font color="blue">stockholders</font> may consider in their best     <font color="blue">interests may</font> not occur</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>Substantial  <font color="blue">future sales</font> of our <font color="blue"><font color="blue">common stock</font> by us</font> or by our existing     <font color="blue">stockholders</font> could cause our stock price to fall</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">equity financings</font> or other share <font color="blue">issuances by us</font>, including     <font color="blue">shares issued</font> in connection with strategic alliances, could <font color="blue">adversely</font> affect     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales by existing <font color="blue">stockholders</font> of a     large number of shares of our <font color="blue">common stock</font> in the <font color="blue">public market</font> or the     <font color="blue">perception</font> that <font color="blue">additional</font> sales could occur could cause the <font color="blue">market price</font> of     our <font color="blue">common stock</font> to drop</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, 52cmam038cmam850 shares of our     common  stock were outstanding, of which 51cmam732cmam791 shares were freely     tradable and 306cmam059 shares were transferable in <font color="blue"><font color="blue">accordance</font> with certain</font>     volume,  notice  and manner of <font color="blue">sale restrictions under</font> Rule 144 of the     <font color="blue">Securities Act </font>of 1933</td>
    </tr>
    <tr>
      <td>If we do not progress in our <font color="blue">programs as</font> anticipated, our <font color="blue">stock price could</font>     decrease</td>
    </tr>
    <tr>
      <td>For planning purposes, we estimate the timing of a variety of clinical,     <font color="blue">regulatory</font> and other <font color="blue">milestones</font>, such as when a certain <font color="blue">product candidate</font>     will enter clinical <font color="blue">development</font>, when a <font color="blue">clinical trial</font> will be completed or     when an <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> will be filed</td>
    </tr>
    <tr>
      <td>Our estimates are <font color="blue">based on</font>     present  facts  and  a  variety of <font color="blue">assumptions</font></td>
    </tr>
    <tr>
      <td>Many of the underlying     <font color="blue">assumptions</font> are outside of our control</td>
    </tr>
    <tr>
      <td>If <font color="blue">milestones</font> are not achieved when     we estimated that they would be, <font color="blue">investors could</font> be <font color="blue">disappointed</font>, and our     <font color="blue"><font color="blue">stock price may</font> decrease</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may</font> be volatile, and you may not be able to resell your     shares at or above your <font color="blue">purchase price</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock prices</font> and the <font color="blue">market price</font>s for securities of bio<font color="blue">technology</font>     companies in general have been <font color="blue">highly volatile</font>, with recent <font color="blue">significant</font>     price and <font color="blue">volume fluctuations</font>, and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font> in the     future</td>
    </tr>
    <tr>
      <td>You     may  not be able to sell your <font color="blue">shares quickly</font> or at the <font color="blue">market price</font> if     trading in our stock is not active or the volume is low</td>
    </tr>
    <tr>
      <td>The following     factors, in addition to other <font color="blue">risk factors described</font> in this section, may     have a <font color="blue">significant</font> <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>, some of     which are beyond our control:           •   <font color="blue">development</font>s regarding, or the results of, our <font color="blue"><font color="blue">clinical trial</font>s</font>,     including TELCYTA <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   <font color="blue">announcement</font>s of <font color="blue">technological innovations</font> or <font color="blue">new commercial products</font>     by our <font color="blue">competitors</font> or us;           •   <font color="blue">development</font>s concerning <font color="blue">proprietary</font> rights, including patents;           •   <font color="blue">development</font>s concerning our <font color="blue"><font color="blue">collaboration</font>s</font>; publicity regarding actual     or <font color="blue">potential medical</font> results relating to products under <font color="blue">development</font> by our     <font color="blue">competitors</font> or us;           •   <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue">United States </font>and foreign countries;           •   <font color="blue">litigation</font>;           •   economic and other <font color="blue">external factors</font> or other disaster or crisis; or           •   period-to-period fluctuations in our financial results</td>
    </tr>
    <tr>
      <td>We are required to recognize expense for stock based <font color="blue">compensation</font> related to     employee  stock  options and <font color="blue"><font color="blue">employee stock</font> purchases</font>, and there is no     assurance that the expense we are required to recognize <font color="blue">measures accurately</font>     the value of our share-based payment awards, and the <font color="blue">recognition</font> of this     <font color="blue">expense could</font> cause the <font color="blue">trading price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>1, 2006, we adopted SFAS 123R which requires the <font color="blue">measurement</font> and     <font color="blue">recognition</font> of <font color="blue"><font color="blue">compensation</font> expense</font> for all stock-based <font color="blue">compensation</font> based     on estimated <font color="blue"><font color="blue">fair value</font>s</font></td>
    </tr>
    <tr>
      <td>As a result, our operating results for the first     quarter of 2006 and for <font color="blue"><font color="blue">future periods</font> will contain</font> a charge for stock-based     <font color="blue">compensation</font> related to <font color="blue"><font color="blue">employee stock</font> options</font> and <font color="blue"><font color="blue">employee stock</font> purchases</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">application</font> of SFAS 123R requires the use of an option-pricing model to     determine the <font color="blue">fair value</font> of share-based payment awards</td>
    </tr>
    <tr>
      <td>This <font color="blue">determination</font>     of fair                                           23     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>value is <font color="blue">affected by</font> our stock price as well as <font color="blue">assumptions</font> regarding a     number of <font color="blue">highly complex</font> and <font color="blue">subjective variables</font></td>
    </tr>
    <tr>
      <td>These variables include,     but are not limited to, our expected <font color="blue">stock price volatility over</font> the term of     the  awards,  and  actual and projected <font color="blue"><font color="blue">employee stock</font> option exercise</font>     <font color="blue">behaviors</font></td>
    </tr>
    <tr>
      <td>Option-pricing models were developed for use in estimating the     value of <font color="blue">traded options</font> that have no vesting or <font color="blue">hedging restrictions</font> and are     fully  transferable</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>our <font color="blue"><font color="blue">employee stock</font> options</font> have certain     <font color="blue">characteristics</font> that are <font color="blue">significant</font>ly <font color="blue">different</font> from <font color="blue">traded options</font>, and     because changes in the subjective <font color="blue">assumptions</font> can <font color="blue">materially affect</font> the     estimated value, in <font color="blue">management</font>’s opinion the <font color="blue">existing valuation models may</font>     not provide an accurate measure of the <font color="blue">fair value</font> of our <font color="blue">employee stock</font>     options</td>
    </tr>
    <tr>
      <td>Although the <font color="blue">fair value</font> of <font color="blue"><font color="blue">employee stock</font> options</font> is determined in     <font color="blue">accordance</font> with SFAS 123R and SAB 107 using an option-pricing model, that     value  may  not  be <font color="blue">indicative</font> of the <font color="blue">fair value</font> observed in a willing     buyer/willing seller market transaction</td>
    </tr>
    <tr>
      <td>We expect that our adoption of SFAS 123R will have a material <font color="blue">impact on</font> our     <font color="blue">financial statements</font> and results of <font color="blue">operations</font> and this <font color="blue">will continue</font> to be     the case for <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effect that this adverse     <font color="blue">impact on</font> our reported operating results will have on the <font color="blue">trading price</font> of     our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>